801303-32-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Propanone, 1-(4-bromo-2-fluorophenyl)-2-methylis used as a building block in the synthesis of various organic compounds for pharmaceutical applications. Its specific properties may make it suitable for use in certain chemical reactions or as a precursor in the production of other chemicals with potential biological activity, which could be investigated for use in medicinal products.
Used in Agrochemical Industry:
1-Propanone, 1-(4-bromo-2-fluorophenyl)-2-methylis used as a precursor in the production of agrochemicals. Its unique structure and properties may contribute to the development of new agrochemicals with improved efficacy and selectivity, enhancing crop protection and yield.
Used in Materials Science:
1-Propanone, 1-(4-bromo-2-fluorophenyl)-2-methylis used in materials science for the development of new materials with specific properties. Its potential applications include the synthesis of polymers, coatings, and other materials with tailored characteristics, such as improved stability, durability, or functionality.
Overall, 1-Propanone, 1-(4-bromo-2-fluorophenyl)-2-methylis a versatile chemical that has potential applications in a range of industries, including pharmaceuticals, agrochemicals, and materials science, due to its unique structure and properties.

Upstream product

• 1068-55-9 isopropylmagnesium chloride 
• 801303-33-3 4-bromo-2-fluoro-N-methoxy-N-methylbenzamide 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Downstream Products

• 801303-34-4 3-fluoro-4-(2-methylpropionyl)benzoic acid 
• 1391123-54-8 6-bromo-3-isopropyl-1H-indazole 

Relevant academic research and scientific papers

5-(3-isopropyl benzisoxazol)pyrazin-2-amine and preparation method thereof

The invention discloses 5-(3-isopropyl benzisoxazol)pyrazin-2-amine and a preparation method thereof. The 5-(3-isopropyl benzisoxazol)pyrazin-2-amine has the structural formula represented by the formula (I). The compound is a new benzisoxazole compound, provides a new bactericidal drug for people, and further broadens research fields of benzoisoxazole compounds. Moreover, the reaction total yield for preparation of the compound is high, and the process is simple and is suitable for industrialized production.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS

The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejecti